HIF-1α and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides

Research output: Contribution to journalArticle

Abstract

Prostate cancer possesses its unique feature of low proliferation rate and slow growth. Ca2+-induced apoptosis is not dependent on cell cycle progression and targeting this pathway could circumvent the problems encountered using current cytotoxic chemotherapies for prostate cancer. Hypoxia-inducible factor 1α (HIF-1α) is another novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides, known inhibitors of the alpha-subunit of sarcolemmal Na +K+-ATPase, were recently found to block tumor growth via the inhibition of HIF-1α synthesis. Thus, cardiac glycosides disrupt two important cellular pathways and, therefore, may be useful as an anticancer therapy. This review will focus on HIF-1α and calcium signaling as novel cancer drug targets in prostate cancer. The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed.

Original languageEnglish (US)
Pages (from-to)881-887
Number of pages7
JournalCurrent Cancer Drug Targets
Volume9
Issue number7
DOIs
StatePublished - Nov 2009

Fingerprint

Hypoxia-Inducible Factor 1
Cardiac Glycosides
Calcium Signaling
Prostatic Neoplasms
Digoxin
Neoplasms
Therapeutics
Growth
Pharmaceutical Preparations
Cell Cycle
Apoptosis
Drug Therapy

Keywords

  • Calcium
  • Cardiac glycosides
  • Digoxin
  • HIF-1α
  • Prostate cancer

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

HIF-1α and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. / Lin, J.; Denmeade, S.; Carducci, M. A.

In: Current Cancer Drug Targets, Vol. 9, No. 7, 11.2009, p. 881-887.

Research output: Contribution to journalArticle

@article{7a48e922abfc4f4b883869a4cf34e37f,
title = "HIF-1α and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides",
abstract = "Prostate cancer possesses its unique feature of low proliferation rate and slow growth. Ca2+-induced apoptosis is not dependent on cell cycle progression and targeting this pathway could circumvent the problems encountered using current cytotoxic chemotherapies for prostate cancer. Hypoxia-inducible factor 1α (HIF-1α) is another novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides, known inhibitors of the alpha-subunit of sarcolemmal Na +K+-ATPase, were recently found to block tumor growth via the inhibition of HIF-1α synthesis. Thus, cardiac glycosides disrupt two important cellular pathways and, therefore, may be useful as an anticancer therapy. This review will focus on HIF-1α and calcium signaling as novel cancer drug targets in prostate cancer. The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed.",
keywords = "Calcium, Cardiac glycosides, Digoxin, HIF-1α, Prostate cancer",
author = "J. Lin and S. Denmeade and Carducci, {M. A.}",
year = "2009",
month = "11",
doi = "10.2174/156800909789760249",
language = "English (US)",
volume = "9",
pages = "881--887",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - HIF-1α and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides

AU - Lin, J.

AU - Denmeade, S.

AU - Carducci, M. A.

PY - 2009/11

Y1 - 2009/11

N2 - Prostate cancer possesses its unique feature of low proliferation rate and slow growth. Ca2+-induced apoptosis is not dependent on cell cycle progression and targeting this pathway could circumvent the problems encountered using current cytotoxic chemotherapies for prostate cancer. Hypoxia-inducible factor 1α (HIF-1α) is another novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides, known inhibitors of the alpha-subunit of sarcolemmal Na +K+-ATPase, were recently found to block tumor growth via the inhibition of HIF-1α synthesis. Thus, cardiac glycosides disrupt two important cellular pathways and, therefore, may be useful as an anticancer therapy. This review will focus on HIF-1α and calcium signaling as novel cancer drug targets in prostate cancer. The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed.

AB - Prostate cancer possesses its unique feature of low proliferation rate and slow growth. Ca2+-induced apoptosis is not dependent on cell cycle progression and targeting this pathway could circumvent the problems encountered using current cytotoxic chemotherapies for prostate cancer. Hypoxia-inducible factor 1α (HIF-1α) is another novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides, known inhibitors of the alpha-subunit of sarcolemmal Na +K+-ATPase, were recently found to block tumor growth via the inhibition of HIF-1α synthesis. Thus, cardiac glycosides disrupt two important cellular pathways and, therefore, may be useful as an anticancer therapy. This review will focus on HIF-1α and calcium signaling as novel cancer drug targets in prostate cancer. The possible application of digoxin and other cardiac glycosides in cancer therapeutics especially in prostate cancer is discussed.

KW - Calcium

KW - Cardiac glycosides

KW - Digoxin

KW - HIF-1α

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=72849153162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849153162&partnerID=8YFLogxK

U2 - 10.2174/156800909789760249

DO - 10.2174/156800909789760249

M3 - Article

C2 - 20025575

AN - SCOPUS:72849153162

VL - 9

SP - 881

EP - 887

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -